Author

V. Di Cristanziano

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

F. Klein· 3 shared L. Gieselmann· 3 shared M. Koch· 3 shared C. Kreer· 2 shared H. Gruell· 2 shared K. Vanshylla· 2 shared M. Korenkov· 2 shared M. S. Ercanoglu· 2 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

F. Klein

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintJun 6, 2022

The unique ORF8 protein from SARS-CoV-2 binds to human dendritic cells and induces a hyper-inflammatory cytokine storm

M. Hamdorf, T. Imhof, B. A. Bailey-Elkin…·F. Bock

This study shows that SARS-CoV-2's ORF8 protein binds to human dendritic cells, induces cytokine storms, and may be a target for therapeutic intervention.

DOI 10.1101/2022.06.06.494969

humanproteomics

𝕏 PostBluesky

ImmunologybioRxivSep 8, 2021

No substantial pre-existing B cell immunity against SARS-CoV-2 in healthy adults

M. S. Ercanoglu, L. Gieselmann, S. Daehling…·F. Klein

The paper analyzes B cell immunity in unexposed adults and finds no substantial pre-existing antibody or B cell response to SARS-CoV-2.

DOI 10.1016/j.isci.2022.103951

humanproteomics

𝕏 PostBluesky

ImmunologybioRxivJun 12, 2020

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients

C. Kreer, M. Zehner, T. Weber…·F. Klein

This study isolates potent SARS-CoV-2-neutralizing antibodies from COVID-19 patients as early as 8 days post-diagnosis and identifies precursor B cells in healthy individuals.

DOI 10.1016/j.cell.2020.06.044

humanproteomics

𝕏 PostBluesky